Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer |
| |
| Affiliation: | 1. Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China;2. Laboratory Animal Center, Guangzhou Medical University, Guangzhou 510182, China;3. Guangzhou HYY Precision&Translation Medicine Institute, Guangzhou 510300, China;1. Department of Respiratory Medicine, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, 215028, PR China;2. Department of Nursing, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, 215028, PR China;3. Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai, 200433, PR China;4. Department of Oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu, 222002, PR China;1. Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China;2. Department of General Surgery, Tianjin Fifth Central Hospital, Tianjin, 300450, China;3. Department of Radiology, Tianjin Fifth Central Hospital, Tianjin, 300450, China;1. Department of Hepatobiliary Surgery, Heilongjiang Province Second Cancer Hospital, Harbin 150088, China;2. Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China;3. First Department of General Surgery, Second Hospital of Harbin City, Harbin 150056, China;1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China;2. Department of Radiotherapy, Shantou Central Hospital, Shantou, 515031, China;1. UCLA School of Dentistry and Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA;2. Stomatological Hospital, Southern Medical University, Guangzhou, 510280, China |
| |
| Abstract: | BackgroundFK506 binding protein 9 (FKBP9) has been reported and identified for a long time, but its relationship with cancer is rarely studied. For example, the role of FK506 binding protein 9 in prostate cancer (PCa) is still unclear. Therefore, we decided to detect the expression level of FKBP9 in PCa and explore its clinical significance.MethodsThe expression level of FKBP9 protein was detected by immunohistochemistry. In addition, it was demonstrated by high-throughput sequencing of mRNA levels in the TCGA (cancer genome atlas) dataset of 499 patients. Kaplan-meier analysis and Cox proportional hazard regression model were used to evaluate the relationship between FKBP9 expression and survival in prostate cancer patients.ResultsThe expression of FKBP9 was localized in the cytoplasm, which in normal prostate tissues was obviously lower than that in PCa tissues (P = 0.001). High expression of FKBP9 was related with lymph node metastasis (P = 0.022) and distant metastasis (P = 0.028). Kaplan-Meier survival analysis revealed that the BCR-free survival of PCa patients with high FKBP9 level was significantly shortened (P=0.041).ConclusionsFKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients. |
| |
| Keywords: | FKBP9 Prostate cancer Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
